Citizens initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $34 price target Ronde-Cel, the company’s lead dual-targeting CD19/CD20 CAR T-cell therapy, has demonstrated “promising” Phase 1/2 clinical data in the multi-billion-dollar B-cell lymphoma market, the analyst tells investors in a research note. The firm believes Lyell shares represent an attractive investment opportunity with 36% downside in a bear case and 209% upside in a bull case.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- LYEL Earnings this Week: How Will it Perform?
- Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know
- Lyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target
- Lyell Immunopharma initiates patient dosing in PiNACLE-H2H Phase 3 trial